Printer Friendly

ALZHEIMER'S CHANGES INDUCED IN LAB TESTS; MAY PROVIDE MODEL FOR DRUG DEVELOPMENT

ALZHEIMER'S CHANGES INDUCED IN LAB TESTS; MAY PROVIDE MODEL FOR DRUG
 DEVELOPMENT
 IRVINE, Calif., Oct. 1 /PRNewswire/ -- Cortex Pharmaceuticals, Inc. (NASDAQ: CORX) today announced that Dr. Carl W. Cotman, a professor at the University of California at Irvine and a Cortex founder, has for the first time demonstrated, in his academic laboratories, that aggregated synthetic beta amyloid protein induces in neurons the characteristic pathological changes that are strongly associated with the cognitive deficits observed in Alzheimer's patients.
 In work reported in the September issue of the British neuroscience journal NeuroReport, Cotman's team exposed cultured rat hippocampal neurons to aggregates of synthetic beta amyloid peptides. After two days, the cells in contact with the beta amyloid aggregates demonstrated the characteristic morphological changes associated with Alzheimer's disease, such as beading, fragmentation, terminal swelling and tortuous growth patterns. According to the scientist, these morphological changes are a dominant contributor to the cognitive deficits that are seen in Alzheimer's patients.
 "Last year, my laboratory was the first to report that the biological effects of beta amyloid protein are profoundly affected by its state of aggregation," said Cotman. "We have now been able to show, in a simple model system, that aggregated beta amyloid consistently brings on the form of brain cell deterioration that is observed in the disease itself. This provides convincing evidence that there is a direct cause-and-effect relationship between aggregated beta amyloid protein and the unique pattern of neuronal changes seen in Alzheimer's disease, and opens up new avenues for drug research."
 "The most effective drug development programs are based on laboratory models that accurately mimic the human disease. Dr. Cotman's discoveries have provided Cortex with just such a tool," said Dr. Jay D. Glass, interim president and chief executive officer. "Our in-house team will benefit greatly from our exclusive consulting arrangement with Dr. Cotman as they work to apply his findings to the development of drugs for treatment of this devastating disease."
 Cortex is a neurological drug discovery company that is developing products for the treatment and diagnosis of age-related diseases and disorders of the brain.
 -0- 10/01/92
 CONTACT: Jay Glass, Ph.D., interim president and CEO of Cortex, 714-727-3157, or Fred Spar of Kekst & Co., 212-593-2655, for Cortex
 (CORX) CO: CORTEX PHARMACEUTICALS IN: MTC ST: CA -- LA017 -- X920 10/01/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 1, 1992
Words:383
Previous Article:BRAJDAS CORP. HOLDS ANNUAL MEETING OF SHAREHOLDERS
Next Article:CHIQUITA ANNOUNCES EXTENSION AND AMENDMENT OF EXCHANGE OFFER
Topics:


Related Articles
SIBIA Reports Prolonged Cognitive-Enhancing Effect of Its Lead Nicotinic Acetylcholine Receptor Compound in Pre-Clinical Models of Parkinson's Disease
NeoTherapeutics Announces Equity-Based Line of Credit
Neurogen Updates Status of Partnered Drug Development Programs.
Preclinical Results Announced for Alzheimer's Drug, NCX 2216.
Guilford Announces Start of Phase II Study in Parkinson's Disease and Receipt Of New Patent Covering Neuroimmunophilin Ligands.
Neurochem announces the achievement of an important drug development milestone for Alzheimer's Disease.
Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration.
Panacea Pharmaceuticals Launches CLIA Compliant Diagnostic Testing Laboratory.
New test can help assess efficacy of Alzheimer's drugs.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters